SUBSCRIBE

Breaking News on Dairy Processing & Markets

News > Manufacturers

Read more breaking news

 

 

Nature One Dairy and Sinopharm sign China infant formula deal

Post a comment

By Jim Cornall+

12-Jun-2017

Sinopharm and Nature One Dairy have signed an agreement for the production of infant formula for the Chinese market.
Sinopharm and Nature One Dairy have signed an agreement for the production of infant formula for the Chinese market.

Australia’s Nature One Dairy and The China National Pharmaceutical Group Corporation (Sinopharm) have signed a strategic partnership agreement to work on infant milk formula, specialized milk powder products and other health-related products for export to China.

Under the agreement, Nature One Dairy will produce an all-Australian-made infant milk formula brand in its Australian manufacturing facility for Sinopharm for China.

Under China’s new policy on infant milk formula, which takes effect January 1, 2018, manufacturers are limited in the number of brands that can be registered in China. The new policy is part of the Chinese government’s measures to introduce and enforce strict food regulations to ensure food safety.

Nick Dimopoulos, CEO of Nature One Dairy, said the company’s aim is to produce a wide range of formulated products to meet the demands of different consumer groups.

Sinopharm produces the infant formula brand Happy Veve.

About Nature One Dairy

Nature One Dairy is a dairy manufacturing company based in Melbourne, Australia producing a range of specialized dairy products designed for every age group ranging from infants to the elderly.

Nature One Dairy’s products are manufactured in a facility that has been specifically designed with infant formula in mind and is certified by the Department of Agriculture and Dairy Food Safety Victoria (DFSV).

About Sinopharm

China National Pharmaceutical Group Corporation (Sinopharm) is the largest medical and healthcare group under the direct leadership of the State-owned Assets Supervision and Administration Commission of the State Council.

In 2015, the total sales revenue of Sinopharm was more than 270bn RMB ($39.7bn).

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...